Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT04657094Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in autoimmune hemolytic anemia (AIHA), chronic lymphocytic leukemia (CLL), sponsored by City of Hope. Started Mar 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
autoimmune hemolytic anemia (AIHA)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04657094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657094.